4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome

4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome

Oncologic emergencies are acute, life-threatening metabolic, haematologic, or structural complications resulting from rapid tumor cell breakdown or physical tumor expansion. Specialist oncology dietitians must quickly recognize clinical signs, understand the underlying pathophysiology, and immediately execute specialized Medical Nutrition Therapy (MNT) modifications in coordination with the medical oncology team.

---

Tumor Lysis Syndrome (TLS)

TLS is a severe metabolic emergency triggered by the rapid release of intracellular contents into systemic circulation following massive lysis of malignant cells. It is most common in high-grade hematologic malignancies (Acute Lymphoblastic Leukemia [ALL], Burkitt Lymphoma, Acute Myeloid Leukemia [AML]) and chemosensitive bulky solid tumors.

Cairo-Bishop Diagnostic Criteria for TLS

Laboratory TLS requires $\ge 2$ of the following metabolic electrolyte abnormalities occurring within 3 days before or 7 days after initiating cytotoxic therapy:

1. Hyperuricemia: Uric acid $\ge 8.0\text{ mg/dL}$ (causes acute renal failure due to insoluble uric acid crystal precipitation in renal tubules).
2. Hyperkalemia: Potassium $\ge 6.0\text{ mEq/L}$ (causes fatal cardiac arrhythmias and sudden cardiac arrest).
3. Hyperphosphatemia: Phosphorus $\ge 4.5\text{ mg/dL}$ in adults (causes calcium-phosphate crystal deposition in renal microvasculature and soft tissues).
4. Hypocalcemia: Corrected Calcium $\le 7.0\text{ mg/dL}$ or ionized $\text{Ca} < 1.12\text{ mmol/L}$ (secondary to massive calcium-phosphate binding; causes tetany, seizures, QT prolongation).

Medical & MNT Management of TLS

• Vigorous Intravenous Hydration: $2.0\text{ to }3.0\text{ L/m}^2/\text{day}$ (or 3 L/day) of isotonic saline to maintain high urine output ($\ge 100\text{ mL/m}^2/\text{hr}$).
• Uric Acid Pharmacotherapy:
  • Allopurinol: Xanthine oxidase inhibitor; prevents new uric acid synthesis (does not clear pre-existing uric acid).
  • Rasburicase (Recombinant Urate Oxidase): Enzymatically converts existing insoluble uric acid into highly soluble allantoin, rapidly lowering serum uric acid within hours. Contraindicated in G6PD deficiency.
• Critical MNT Protocol: STRICTLY ELIMINATE potassium and phosphorus from enteral (EN) or parenteral (PN) nutrition formulations during acute TLS until electrolyte balance and renal function normalize. Withhold calcium supplementation unless symptomatic hypocalcemia occurs, to avoid accelerating calcium-phosphate tissue precipitation.

---

Hypercalcemia of Malignancy (HCM)

HCM occurs in up to 30% of advanced cancer patients (squamous cell lung, head/neck, renal cell, breast cancer, multiple myeloma).

Etiologies & Pathophysiology

1. Humoral Hypercalcemia of Malignancy (HHM) (~80% of cases): Driven by systemic tumor secretion of Parathyroid Hormone-Related Protein (PTHrP), which binds renal and bone PTH receptors, stimulating massive osteoclast bone resorption and renal tubular calcium reabsorption.
2. Local Osteolytic Hypercalcemia (~20% of cases): Direct bone destruction by skeletal metastases mediated by local cytokines (IL-1, TNF, RANKL).

Corrected Calcium Formula & Calculation

Because ~40% of serum calcium is bound to albumin, hypoalbuminemia masks severe hypercalcemia. Corrected calcium MUST be calculated:

$\text{Corrected Calcium (mg/dL)} = \text{Measured Serum Calcium (mg/dL)} + 0.8 \times (4.0 - \text{Serum Albumin [g/dL]})$

Worked Clinical Example: Measured Serum $\text{Ca} = 11.2\text{ mg/dL}$, Serum $\text{Albumin} = 1.8\text{ g/dL}$. $\text{Corrected Ca} = 11.2 + 0.8 \times (4.0 - 1.8) = 11.2 + 0.8 \times (2.2) = 11.2 + 1.76 = 12.96\text{ mg/dL } (\text{Severe Hypercalcemia!})$

Clinical Presentation & Medical Management

• Symptoms: "Stones, bones, abdominal groans, psychiatric overtones" (polyuria, polydipsia, nephrolithiasis, severe constipation, nausea, confusion, lethargy, coma, shortened QT interval).
• Medical Interventions: Vigorous IV isotonic saline hydration ($2 ext{--}4 ext{ L/day}$) plus IV bisphosphonates (Zoledronic acid 4 mg IV) or RANKL inhibitors (Denosumab 120 mg SQ).
• CRITICAL MNT RULE: Dietary calcium restriction is INEFFECTIVE for Hypercalcemia of Malignancy. HCM is driven by systemic osteoclast bone resorption and tumor PTHrP activity, NOT by intestinal calcium absorption. Restricting dietary calcium does NOT lower serum calcium and unnecessarily compromises nutritional status.

---

Superior Vena Cava (SVC) Syndrome & Malignant Bowel Obstruction (MBO)

Superior Vena Cava (SVC) Syndrome

• Pathophysiology: Extrinsic compression or thrombosis of the SVC by thoracic malignancies (small cell lung cancer, non-small cell lung cancer, mediastinal lymphoma).
• Clinical Manifestations: Facial and periorbital edema, neck vein distension ("Stokes sign"), dyspnea, orthopnea, upper extremity edema.
• Supportive MNT Care: Elevate head of bed ($>45^\circ$) to promote venous drainage. Offer small, soft, easy-to-chew meals during severe dyspnea, avoiding fluid overload.

Malignant Bowel Obstruction (MBO)

• Pathophysiology: Mechanical luminal obstruction or extrinsic compression from peritoneal carcinomatosis in ovarian, colorectal, or gastric cancers.
• Management: Nasogastric decompression, IV hydration, antiemetics, and antisecretory pharmacotherapy (Octreotide 100 to 300 mcg SubQ/IV TID to reduce GI secretion volume).
• MNT & TPN Indications: Low-residue liquid diet for partial obstruction. Total Parenteral Nutrition (TPN) is ethically indicated ONLY if estimated survival exceeds 2 to 3 months, ECOG performance status is 0–2, and TPN aligns with overall goals of care. TPN is non-beneficial in end-of-life cachexia/obstruction with survival $<6$ weeks.

---

Integrated Emergency Case Scenario

Patient Profile: A 52-year-old female with Burkitt lymphoma develops acute TLS 24 hours post-chemotherapy. Labs: Uric acid $11.5\text{ mg/dL}$, Potassium $6.3\text{ mEq/L}$, Phosphorus $6.1\text{ mg/dL}$, Measured Calcium $6.8\text{ mg/dL}$, Albumin $2.5\text{ g/dL}$.

Care Plan Analysis:

1. Diagnostic Verification: Meets Cairo-Bishop TLS criteria (hyperuricemia, hyperkalemia, hyperphosphatemia).
2. Corrected Calcium: $6.8 + 0.8 \times (4.0 - 2.5) = 8.0\text{ mg/dL}$ (mild asymptomatic hypocalcemia secondary to hyperphosphatemia).
3. Immediate Interventions: Administer Rasburicase $0.2\text{ mg/kg}$ IV. Initiate IV isotonic hydration at $3\text{ L/m}^2/\text{day}$.
4. MNT Order: Immediately modify TPN/EN to ZERO potassium and ZERO phosphorus. Hold IV calcium supplementation to avoid tissue calcium-phosphate precipitation.